egnite Brings Renowned Interventional Cardiologist, Rahul Sharma, onto Executive Team as Senior Medical Advisor

egnite Brings Renowned Interventional Cardiologist, Rahul Sharma, onto Executive Team as Senior Medical Advisor

ALISO VIEJO, Calif. – February 16, 2023 –  egnite, Inc., a leading digital-health company in the field of cardiovascular care, is proud to announce the appointment of Rahul P. Sharma, MD, MBBS, FRACP, as its new Senior Medical Advisor.

A renowned interventional cardiologist, Sharma brings a wealth of knowledge and expertise to egnite’s executive team. With over a decade of experience in structural heart disease and transcatheter valve therapy, Sharma will play a key role in shaping egnite’s clinical strategy, advancing the organization’s mission to improve patient care through digital health technologies.

Sharma has a proven track record of success in advancing the field of cardiovascular medicine as an investigator in several national multi-center clinical trials and as a co-author of numerous peer-reviewed scientific articles. As Senior Medical Advisor, Sharma will help shape the real-world evidence strategy for egnite, working closely with healthcare providers to drive improved patient care and outcomes through egnite’s innovative technologies. Sharma will also drive key product evolutions as he advises egnite on technology enhancements that support best-in-class cardiovascular programs and help generate progressive clinical science that advances medicine.  

“We are thrilled to welcome Rahul to the egnite team,” said Joel Portice, CEO of egnite. “His extensive experience and deep knowledge of the clinical landscape will be invaluable as we develop and launch innovative solutions to improve patient outcomes.”

Based in the heart of Silicon Valley, Sharma has fused his passion for science and innovation by working in collaboration with several health tech companies. He is also a co-founder of Synchron, a leading implantable brain-computer interface company looking to restore the lives of patients with neurological diseases. Sharma is currently the Director of Structural Interventions, Associate Director of the Cardiac Catheterization Laboratory, and the Associate Professor of Medicine at a large academic institution.

“I am excited to join the egnite team during the next phase of growth for the company,” said Sharma. “I am committed to using my expertise to improve patient outcomes and make a meaningful difference in the lives of those we serve.”

About egnite, Inc.

egnite is a visionary digital health company born from the innovation of Edwards Lifesciences, committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company partners with leading hospitals and life sciences providers to transformative care delivery for cardiovascular patients. The company is based in Aliso Viejo, Calif., for more information, visit www.egnitehealth.com.

Related Articles

Press

egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none. ALISO VIEJO, Calif., Oct. 21, 2026 — egnite, Inc., a technology company advancing guideline-directed cardiovascular care and real-world evidence, today released its 2026 Benchmark Report

Press

egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026

The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure.  ALISO VIEJO, Calif. — October 13, 2026 — egnite, Inc., a cardiovascular intelligence company that helps clinicians identify and manage patients with untreated heart disease, today announced that Dr. John T. Saxon, Director of the Advanced Cardiac Valve Center at University of Virginia

Publications

Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data

BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions